Advancements in Amyloid-Targeting and Tau PET Offer Hope for Alzheimer's Diagnosis and Treatment

Advancements in amyloid-targeting monoclonal antibodies for the treatment of Alzheimer's disease (AD) show promise in slowing cognitive decline. However, concerns have been raised regarding the cost, adverse reactions, and accessibility of these drugs, particularly for marginalized patients. The high cost of these medications, along with potential adverse events and the need for advanced imaging and outpatient visits, may create barriers to access for individuals with AD. Additionally, there is a lack of representation and data on the efficacy and safety of these drugs in ethnically and racially diverse populations. Further investigation and policy considerations are needed to ensure equitable access to these promising therapies.